Retrospective analysis: erlotinib vs gefitinib in Asian patients with newly diagnosed brain metastases

Patients with exon 19 EGFR mutations and newly diagnosed brain metastases experienced significantly longer overall survival and PFS when treated with erlotinib, compared with patients treated with gefitinib.1

Study overview1

  • This retrospective analysis examined clinical outcomes of Asian patients with EGFR Mut+ NSCLC and newly diagnosed brain metastases, who were treated with either erlotinib or gefitinib.

Key Results

Overall survival1

Patients receiving erlotinib had a statistically significant longer median overall survival than patients treated with gefitinib (p=0.033).

Progression-free survival1

Patients receiving erlotinib had a statistically significant longer median PFS than patients treated with gefitinib (p=0.014).